| Name | Title | Contact Details |
|---|
Greenway Medical Technologies provides the latest in ambulatory healthcare business solutions and services to 20000 healthcare providers and professionals nationwide, in 30 specialties and subspecialties, by enhancing the delivery of patient care
"Eleven uses its proprietary technology platform to create first-of-a-kind protein therapeutics to address unmet needs for ophthalmic diseases. Proteins are able to modulate inflammatory cytokines, key targets in ocular disease that have been difficult to access with conventional therapeutic approaches. A significant untapped opportunity exists for protein therapeutics to address ophthalmic diseases, and Eleven is applying its advanced protein technology and expertise to develop innovative medicines for patients suffering from ocular diseases. Eleven`s team of industry veterans has deep experience in understanding protein science and biologic drug development, designing and conducting clinical trials and, most importantly, applying specific expertise in ophthalmic disease to create novel ocular therapeutics to treat unmet medical needs. Eleven has developed a proprietary pipeline of ophthalmic drug candidates derived from the company`s innovative AMP-Rx protein engineering technology. The company`s initial product candidates are focused on targeting inflammatory cytokines and key targets of ocular disease by blocking the cytokines and modulating the biological processes that drive ocular disease. Current pipeline opportunities include ocular surface diseases such as dry eye disease (DED) and allergic conjunctivitis (AC), and back of the eye diseases such as diabetic macular edema (DME) and uveitis. In addition, Eleven’s proprietary technology has been utilized to prolong the intravitreal half-life of our pipeline products. Beyond its internal drug development programs, Eleven works with collaborators, such as ThromboGenics, to apply its innovative protein therapeutic design capabilities to engineer and develop biotherapeutic products for additional therapeutic targets. EBI-005, Eleven`s lead product candidate, is a novel interleukin-1 (IL-1) receptor antagonist in Phase 3 clinical development as one of the first topically administered proteins for the treatment of DED and AC, two inflammatory diseases at the surface of the eye."
Pam Gene is a Cambridge, MA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
himagine solutions inc. is a leading healthcare outsourcing solutions provider with the largest team of inpatient and outpatient coders in the U.S. Our professional HIM outsourcing services include basic staff augmentation as well as more strategic managed coding solutions including full department outsourcing through our Enterprise HIM offering to support more than 250 healthcare providers across the U.S. With our significant and growing base of HIM Subject Matter Experts we provide support for all of our offerings to ensure our client partners receive the most value from our services.
Life-Tech is a Stafford, TX-based company in the Healthcare, Pharmaceuticals, and Biotech sector.